Indaptus Therapeutics Inc
NASDAQ:INDP
Indaptus Therapeutics Inc
Research & Development
Indaptus Therapeutics Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Indaptus Therapeutics Inc
NASDAQ:INDP
|
Research & Development
-$9m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$8.8B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
Research & Development
-$98m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-17%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
Indaptus Therapeutics Inc
Glance View
Indaptus Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas. The company designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, is in pre-clinical development. Its platform is based on the hypothesis that require anti-tumor immunotherapy to activate both innate and adaptive cellular immunity in both tumors and immune organs. Its approach uses multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs) in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. Its intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and hepatitis B virus (HBV) infection.
See Also
What is Indaptus Therapeutics Inc's Research & Development?
Research & Development
-9m
USD
Based on the financial report for Sep 30, 2025, Indaptus Therapeutics Inc's Research & Development amounts to -9m USD.
What is Indaptus Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-4%
Over the last year, the Research & Development growth was -32%. The average annual Research & Development growth rates for Indaptus Therapeutics Inc have been -19% over the past three years , -4% over the past five years .
